Myopericarditis with hemorrhagic pericardial effusion following BNT162b2 mRNA COVID-19 vaccine

Generette, Gabriela S.; Troyer, James; Hemenway, Alice N.; Zoubi, Moamen Al

doi:10.1016/j.idcr.2022.e01511

Cited by 3 publications

(4 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The patient recovered with ibuprofen and colchicine. 6 A second case of hemorrhagic pericardial effusion was reported in a 64-year-old man with chest pain and dyspnea one week following second dose of the Moderna (mRNA-1273) COVID-19 vaccination. 7 The patient's symptoms resolved with pericardiocentesis and colchicine.…”

Section: Brown Hospital Medicinementioning

confidence: 99%

“…3 Two prior cases of hemorrhagic pericardial effusion associated with mRNA COVID-19 vaccination are reported, without tamponade. 6,7 A 74-year-old man with a history of alcoholic cirrhosis and hypertension without COVID-19 exposure or other preceding illness, presented with fever, chills, chest pain, and back pain two weeks following sec-ond dose of BNT162b2 (BioNTech/Pfizer) vaccine. 6 Pericardiocentesis and drainage were performed with 560 cc of bloody fluid.…”

Section: Brown Hospital Medicinementioning

confidence: 99%

“…6,7 A 74-year-old man with a history of alcoholic cirrhosis and hypertension without COVID-19 exposure or other preceding illness, presented with fever, chills, chest pain, and back pain two weeks following sec-ond dose of BNT162b2 (BioNTech/Pfizer) vaccine. 6 Pericardiocentesis and drainage were performed with 560 cc of bloody fluid. The patient recovered with ibuprofen and colchicine.…”

Section: Brown Hospital Medicinementioning

confidence: 99%

“…1,2 Cardiac tamponade has been reported following mRNAbased COVID-19 vaccination and COVID-19 infection. [3][4][5][6][7][8][9][10] Globally, there have been approximately 596 million cases of COVID-19 and 6.4 million reported deaths as of July 2022. Over 12.6 billion vaccination doses have been provided over 184 countries, which averages to be 161 injections per 100 persons worldwide.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Large Hemorrhagic Pericardial Effusion and Cardiac Tamponade Following BNT162b2 (BioNTech/Pfizer) Vaccine

Nguyen

Olenik

2022

Journal of Brown Hospital Medicine

View full text Add to dashboard Cite

The introduction of mRNA-based COVID-19 vaccinations has been useful in decreasing risks of severe illness with COVID-19 infection. Cardiac tamponade is a rare cardiovascular emergency that has been observed following both mRNA-based COVID-19 vaccinations and COVID-19 infections. We report the first case of a hemorrhagic pericardial effusion with cardiac tamponade in a 52-year-old woman occurring one week following the second dose of the BNT162b2 (BioNTech/Pfizer) SARS-CoV-2 vaccination. The time sequence in this case report correlates with reports submitted to the Vaccine Adverse Event Reporting System (VAERS), which indicates that cases of pericarditis following mRNA vaccination most commonly occur within 1-2 weeks following the second dose of vaccination.

show abstract

Section: Brown Hospital Medicinementioning

confidence: 99%

Section: Brown Hospital Medicinementioning

confidence: 99%

Section: Brown Hospital Medicinementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Large Hemorrhagic Pericardial Effusion and Cardiac Tamponade Following BNT162b2 (BioNTech/Pfizer) Vaccine

Nguyen

Olenik

2022

Journal of Brown Hospital Medicine

View full text Add to dashboard Cite

show abstract

Tozinameran

2022

Reactions Weekly

View full text Add to dashboard Cite

Myocarditis and coronavirus disease 2019 vaccination: A systematic review and meta-summary of cases

Saputra¹,

Kurniawan²,

Trilistyoati³

et al. 2023

Biomol Biomed

View full text Add to dashboard Cite

Vaccination is significant to control, mitigate, and recover from the destructive effects of coronavirus disease 2019 (COVID-19). The incidence of myocarditis following COVID-19 vaccination has been increasing and growing public concern; however, little is known about it. This study aimed to systematically review myocarditis following COVID-19 vaccination. We included studies containing individual patient data of myocarditis following COVID-19 vaccination published between January 1, 2020 and September 7, 2022 and excluded review articles. Joanna Briggs Institute critical appraisals were used for risk of bias assessment. Descriptive and analytic statistics were performed. A total of 121 reports and 43 case series from five databases were included. We identified 396 published cases of myocarditis and observed that the majority of cases was male patients, happened following the second dose of mRNA vaccine administration, and experienced chest pain as a symptom. Previous COVID-19 infection was significantly associated (p < 0.01; OR, 5.74; 95% CI, 2.42–13.64) with the risk of myocarditis following the administration of the first dose, indicating that its primary mechanism is immune-mediated. Moreover, 63 histopathology examinations were dominated by non-infective subtypes. Electrocardiography and cardiac marker combination is a sensitive screening modality. However, cardiac magnetic resonance is a significant noninvasive examination to confirm myocarditis. Endomyocardial biopsy may be considered in confusing and severe cases. Myocarditis following COVID-19 vaccination is relatively benign, with a median length of hospitalization of 5 days, intensive care unit admission of <12%, and mortality of <2%. The majority was treated with nonsteroidal anti-inflammatory drugs, colchicine, and steroids. Surprisingly, deceased cases had characteristics of being female, older age, non-chest pain symptoms, first-dose vaccination, left ventricular ejection fraction of <30%, fulminant myocarditis, and eosinophil infiltrate histopathology.

show abstract

Myopericarditis with hemorrhagic pericardial effusion following BNT162b2 mRNA COVID-19 vaccine

Cited by 3 publications

References 21 publications

Large Hemorrhagic Pericardial Effusion and Cardiac Tamponade Following BNT162b2 (BioNTech/Pfizer) Vaccine

Large Hemorrhagic Pericardial Effusion and Cardiac Tamponade Following BNT162b2 (BioNTech/Pfizer) Vaccine

Tozinameran

Myocarditis and coronavirus disease 2019 vaccination: A systematic review and meta-summary of cases

Contact Info

Product

Resources

About